Back to top

Syndax Buy Rating Reaffirmed as Analyst Sees Transitory Demand Weakness, Strong Menin Positioning and Pipeline Catalysts Supporting Unchanged $57 Target

Citi analyst Yigal Nochomovitz maintained a Buy rating on Syndax Pharmaceuticals today and set a price target of $57.00. Yigal Nochomovitz has give...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Syndax Pharmaceuticals, Inc. (SNDX)